Geron Corporation (GERN)
Market Cap | 2.47B |
Revenue (ttm) | 520,000 |
Net Income (ttm) | -201.40M |
Shares Out | 593.13M |
EPS (ttm) | -0.35 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 6,071,089 |
Open | 4.340 |
Previous Close | 4.340 |
Day's Range | 4.160 - 4.370 |
52-Week Range | 1.640 - 5.340 |
Beta | 0.43 |
Analysts | Strong Buy |
Price Target | 6.93 (+66.19%) |
Earnings Date | Aug 1, 2024 |
About GERN
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquarte... [Read more]
Financial Performance
In 2023, Geron's revenue was $237,000, a decrease of -60.23% compared to the previous year's $596,000. Losses were -$184.13 million, 29.8% more than in 2022.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for GERN stock is "Strong Buy." The 12-month stock price forecast is $6.93, which is an increase of 66.19% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/p/8/press11-2489141.jpg)
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggr...
![](https://cdn.snapi.dev/images/v1/p/w/gettyimages-1286971245-17b7494-2469222.jpg)
Geron Stock Soars on FDA Approval of Drug for Patients With Rare Blood Cancers
Geron (GERN) shares skyrocketed over 19% in intraday trading Friday after the Food and Drug Administration (FDA) approved the biopharma company's drug Rytelo for those with rare blood cancers.
![](https://cdn.snapi.dev/images/v1/e/5/218144692-m-normal-none-2468701.jpg)
Geron Corp stock opened 25% up on Friday: here's why
Geron Corp (NASDAQ: GERN) opened about 25% up on Friday after securing an FDA approval for “imetelstat”. Here's what it means for Geron stock The Food & Drug Administration approved its lead asset as...
![](https://cdn.snapi.dev/images/v1/n/e/health-2468095.jpeg)
Very good news for Geron stock price: now what?
Geron Corporation (NASDAQ: GERN) stock price went vertical on Friday as investors cheered the latest actions by the Food and Drug Administration (FDA). After closing at $3.90 on Thursday, the stock su...
![](https://cdn.snapi.dev/images/v1/6/t/euai72jnznpxtjiwqlkdko6waa-2467811.jpg)
Geron shares surge after U.S. FDA approves blood disorder drug
Shares of Geron rose almost 16% on Friday before market, a day after getting its first approval from the U.S. Food and Drug Administration for a drug to treat transfusion-dependent anemia in patients ...
![](https://cdn.snapi.dev/images/v1/j/k/press8-2467599.jpg)
Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that...
![](https://cdn.snapi.dev/images/v1/5/x/press5-2405557.jpg)
Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to t...
![](https://cdn.snapi.dev/images/v1/i/m/conf6-2392781.jpg)
Geron to Announce First Quarter 2024 Financial Results on May 2, 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its first quarter 2024 financial results a...
![](https://cdn.snapi.dev/images/v1/p/o/conf10-2355321.jpg)
Geron to Participate at Upcoming Investor Conferences in April
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executi...
![](https://cdn.snapi.dev/images/v1/4/m/press9-2331044.jpg)
Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of an underwritten offering consisting of 41,999,99...
![](https://cdn.snapi.dev/images/v1/n/i/best-biotech-stocks-to-buy-in--2327901.jpg)
Can Geron Corporation maintain momentum following FDA's backing?
Friday saw an unprecedented surge in the stock of Geron Corporation (NASDAQ:GERN), with shares ending the day up a staggering 92%. This surge, marking a historic milestone for the company, was ignited...
![](https://cdn.snapi.dev/images/v1/t/t/im-512397size1777777777777778w-2326829.jpg)
Geron's stock soars 95% after FDA advisory panel votes in favor of blood-disorder drug
Geron Corp.'s stock rose 95% Friday, after an advisory panel to the Food and Drug Administration voted 12-to-2 in favor of the company's blood-disorder drug imetelstat and said its benefits outweigh t...
![](https://cdn.snapi.dev/images/v1/f/i/press19-2325235.jpg)
Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to t...
![](https://cdn.snapi.dev/images/v1/s/3/eb4k73zanzm6xpf5kyqc4flhlq-2325205.jpg)
Geron's blood disorder drug gets FDA advisers' backing
Advisers to the U.S. Food and Drug Administration on Thursday voted in favor of Geron's blood disorder drug, stating that, based on late-stage trial data, the benefits outweigh treatment associated ri...
![](https://cdn.snapi.dev/images/v1/u/4/qe5utlcc4vmthfbtgom5ndajri-2320129.jpg)
US FDA staff flags concerns about Geron's anemia treatment
The U.S. health regulator's staff on Tuesday flagged concerns that the late-stage trial data on Geron's anemia drug does not show whether the risks of treatment with imetelstat are outweighed by the p...
![](https://cdn.snapi.dev/images/v1/b/c/press5-2298037.jpg)
Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to t...
![](https://cdn.snapi.dev/images/v1/s/d/conf1-2276828.jpg)
Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its fourth quarter and full-year 2023 fina...
![](https://cdn.snapi.dev/images/v1/m/4/press1-2227354.jpg)
Geron to Participate in the B. Riley Securities Virtual Oncology Conference
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executi...
![](https://cdn.snapi.dev/images/v1/5/3/press7-2191872.jpg)
Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDS
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced presentations of data from its IMerge Phase 3 clinical trial ev...
![](https://cdn.snapi.dev/images/v1/g/7/press19-2185439.jpg)
Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced achievement of fifty percent enrollment in the Phase 3 IMpactMF...
![](https://cdn.snapi.dev/images/v1/1/9/press9-2181348.jpg)
Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced publication in The Lancet of results from the IMerge Phase 3 tr...
![](https://cdn.snapi.dev/images/v1/c/h/press3-2173786.jpg)
Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Gaurav Aggarwal, M.D., to the Company's Boar...
![](https://cdn.snapi.dev/images/v1/6/y/conf9-2145458.jpg)
Geron to Participate at Upcoming Investor Conferences in November
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executi...
![](https://cdn.snapi.dev/images/v1/c/v/press18-2136376.jpg)
Geron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDS
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the publication of abstracts from the IMerge Phase 3 clinical t...
![](https://cdn.snapi.dev/images/v1/s/x/press14-2135977.jpg)
Geron Corporation Reports Business Highlights and Third Quarter 2023 Financial Results
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematolog...